Trials / Conditions / Advanced Cholangiocarcinoma

Advanced Cholangiocarcinoma

18 registered clinical trials studyying Advanced Cholangiocarcinoma — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepa NCT07328919	TransThera Sciences (Nanjing), Inc.	Phase 3
Recruiting	Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cho NCT06439485	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Terminated	NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma NCT06420349	Mayo Clinic	Phase 1
Recruiting	Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangi NCT05823311	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 3
Recruiting	At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer NCT05969860	Mayo Clinic	Phase 2
Recruiting	Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement NCT05727176	Taiho Oncology, Inc.	Phase 2
Recruiting	AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease NCT05791448	University of Southern California	Phase 1
Unknown	IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 NCT05805956	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	Phase 1 / Phase 2
Recruiting	Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma NCT05532059	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 2
Terminated	Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Chola NCT04088188	Academic and Community Cancer Research United	Phase 1
Terminated	Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholan NCT04093362	Taiho Oncology, Inc.	Phase 3
Terminated	Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Transloca NCT03773302	QED Therapeutics, a BridgeBio company	Phase 3
Unknown	Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma NCT03982680	Jiangmen Central Hospital	Phase 2
Unknown	Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma NCT03996408	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 1 / Phase 2
Terminated	Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron NCT02982720	Aiwu Ruth He, MD	Phase 2
Completed	Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) NCT02989857	Institut de Recherches Internationales Servier	Phase 3
Terminated	A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma NCT02150967	QED Therapeutics, a BridgeBio company	Phase 2
Approved For Marketing	Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangeme NCT04507503	Taiho Oncology, Inc.	—